Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
In recent transactions disclosed by Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), Mark C. Schneyer, the company’s Executive Vice President and Chief Financial Officer, sold shares of common stock valued at $54,065. The sale, which took place on March 26, involved 3,171 shares at a price of $17.05 per share. This transaction was reportedly made to cover withholding taxes and related tax items associated with the vesting of restricted stock units. According to InvestingPro data, Acadia demonstrates strong financial health with a current ratio of 2.38, indicating robust liquidity management.
Additionally, Schneyer acquired 6,178 shares of common stock on March 25, following the vesting of restricted stock units. These shares were acquired at no cost, as part of a previously established equity compensation plan. After these transactions, Schneyer holds 56,889 shares of Acadia Pharmaceuticals’ common stock directly. The company has shown strong performance with a 31.85% revenue growth in the last twelve months and maintains profitability with a healthy gross margin of nearly 60%. InvestingPro analysis suggests the stock may be undervalued at current levels, with additional insights available in the comprehensive Pro Research Report.
These activities reflect routine financial management by company executives, ensuring compliance with tax obligations while maintaining equity stakes in the company. The company’s solid financial position is reflected in its low debt-to-equity ratio of 0.07 and strong return on assets of 23.39%.
In other recent news, Acadia Pharmaceuticals reported a 12% increase in revenue for the fourth quarter of 2024, reaching $259.6 million. The company’s total revenue for the year amounted to $957.8 million, a 32% increase from the previous year. Acadia’s DAYBUE product achieved net sales of $96.7 million in the fourth quarter, surpassing expectations, and contributing to an overall 97% increase in DAYBUE sales for 2024. Looking forward, Acadia projects 2025 revenue between $1.03 billion and $1.095 billion, with anticipated DAYBUE sales between $380 million and $405 million.
TD Cowen maintained a Buy rating on Acadia Pharmaceuticals, setting a price target of $35, while Citizens JMP adjusted its price target to $37 from $39, maintaining a Market Outperform rating. Both firms highlighted the company’s strong financial performance and potential growth opportunities within its pipeline. Additionally, Acadia Pharmaceuticals announced the issuance of inducement awards to new employees, aligning with Nasdaq Listing Rule 5635(c)(4).
A study published by Acadia in the journal Med confirmed the safety and tolerability of their product, DAYBUE, for young Rett syndrome patients, supporting its FDA approval for use in children aged two and older. These developments reflect Acadia’s ongoing efforts to enhance its market position and deliver value to both patients and shareholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.